Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from ImmunityBio ( (IBRX) ).
On July 24, 2025, ImmunityBio, Inc. announced a securities purchase agreement to sell 29,629,632 shares of its common stock and warrants for an additional 29,629,632 shares, generating approximately $80 million in gross proceeds. The offering is expected to close around July 28, 2025, with Piper Sandler & Co. as the exclusive placement agent. In its Q2 2025 financial results, ImmunityBio reported a 60% increase in revenue to $26.4 million, driven by strong sales of ANKTIVA in BCG-unresponsive bladder cancer. The company also highlighted significant clinical progress, including the initiation of a randomized trial for lung cancer and regulatory discussions on lymphopenia and papillary NMIBC treatments.
The most recent analyst rating on (IBRX) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on ImmunityBio stock, see the IBRX Stock Forecast page.
Spark’s Take on IBRX Stock
According to Spark, TipRanks’ AI Analyst, IBRX is a Neutral.
ImmunityBio’s overall stock score is driven primarily by its challenging financial performance, which includes high leverage and negative cash flows, indicating significant financial instability. While technical analysis shows some positive momentum, valuation metrics further highlight profitability concerns, resulting in a low overall score.
To see Spark’s full report on IBRX stock, click here.
More about ImmunityBio
ImmunityBio is a vertically-integrated commercial stage biotechnology company focused on developing next-generation therapies that enhance the natural immune system to combat cancers and infectious diseases. The company offers a range of immunotherapy and cell therapy platforms aimed at driving and sustaining immune responses for durable and safe disease protection.
Average Trading Volume: 9,193,005
Technical Sentiment Signal: Sell
Current Market Cap: $2.66B
Find detailed analytics on IBRX stock on TipRanks’ Stock Analysis page.